Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Use of drug holidays in women taking bisphosphonates.

Diab DL, Watts NB.

Menopause. 2014 Feb;21(2):195-7. doi: 10.1097/GME.0b013e31829ef343.

PMID:
23921518
2.

Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?

McClung M.

Clin Obstet Gynecol. 2013 Dec;56(4):743-8. doi: 10.1097/GRF.0b013e3182a98295. Review.

PMID:
24177063
3.

Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.

Cole RE.

Postgrad Med. 2011 Mar;123(2):131-44. doi: 10.3810/pgm.2011.03.2271. Review.

PMID:
21474901
4.

Bisphosphonates in the treatment of osteoporosis.

Diab DL, Watts NB.

Endocrinol Metab Clin North Am. 2012 Sep;41(3):487-506. doi: 10.1016/j.ecl.2012.04.007. Epub 2012 Jun 9. Review.

PMID:
22877426
5.

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM.

Am J Med. 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Epub 2012 Nov 20. Review.

PMID:
23177553
6.

Long-term use of bisphosphonates in osteoporosis.

Watts NB, Diab DL.

J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Epub 2010 Feb 19. Review.

PMID:
20173017
7.

Atypical femur fracture during bisphosphonate drug holiday: a case series.

Lovy AJ, Koehler SM, Keswani A, Joseph D, Hasija R, Ghillani R.

Osteoporos Int. 2015 Jun;26(6):1755-8. doi: 10.1007/s00198-015-3063-8. Epub 2015 Apr 2.

PMID:
25832177
8.

Bisphosphonate drug holidays--when, why and for how long?

Anagnostis P, Stevenson JC.

Climacteric. 2015;18 Suppl 2:32-8. doi: 10.3109/13697137.2015.1099092. Epub 2015 Oct 27. Review.

PMID:
26507608
9.

Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting.

Chiha M, Myers LE, Ball CA, Sinacore JM, Camacho PM.

Endocr Pract. 2013 Nov-Dec;19(6):989-94. doi: 10.4158/EP12425.OR.

PMID:
24013976
10.

Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.

Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, Goltzman D, Hanley DA, Hodsman A, Josse R, Jovaisas A, Juby A, Kaiser S, Karaplis A, Kendler D, Khan A, Ngui D, Olszynski W, Ste-Marie LG, Adachi J.

Can Fam Physician. 2014 Apr;60(4):324-33. Review.

11.

[Calcium pros and cons: long term use of bisphosphonates. Bisphophonate should not be used for long term].

Mori S.

Clin Calcium. 2011 Oct;21(10):1547-51. doi: CliCa111015471551. Review. Japanese.

PMID:
21960243
12.

Going on a drug holiday?

Bonnick SL.

J Clin Densitom. 2011 Oct-Dec;14(4):377-83. doi: 10.1016/j.jocd.2011.07.006. No abstract available.

PMID:
22051091
13.

Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.

Chiu WY, Lee JJ, Tsai KS.

J Clin Endocrinol Metab. 2013 Apr;98(4):E723-6. doi: 10.1210/jc.2012-4144. Epub 2013 Mar 7.

PMID:
23471975
14.

[Bisphosphonate-related osteonecrosis of the jaw].

Franken AA, van Blijderveen NJ, Witjes MJ, Netelenbos CJ.

Ned Tijdschr Geneeskd. 2011;155:A3077. Review. Dutch.

PMID:
21486510
15.

[Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].

Soen S.

Clin Calcium. 2011 Oct;21(10):1543-6. doi: CliCa111015431546. Review. Japanese.

PMID:
21960242
16.
17.

[Diphosphonate therapy and osteonecrosis of the jaw].

L√łkken P, Skoglund LA, Skjelbred P.

Tidsskr Nor Laegeforen. 2007 Aug 9;127(15):1945-7. Review. Norwegian. No abstract available.

18.

Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.

Geusens P.

Curr Osteoporos Rep. 2009 Mar;7(1):12-7. Review.

PMID:
19239824
19.

Commentary: drug-associated atypical femoral fractures (DaAFFs): balancing the facts.

Pazianas M, Smith R.

J Clin Endocrinol Metab. 2014 Jul;99(7):2340-2. doi: 10.1210/jc.2014-1375. Epub 2014 Apr 8. No abstract available.

PMID:
24712575
20.

Long-term risks of bisphosphonate therapy.

Watts NB.

Arq Bras Endocrinol Metabol. 2014 Jul;58(5):523-9. Review.

Supplemental Content

Support Center